- Home
- LSB vs PASG Comparison
LSB vs PASG Comparison
Compare LSB & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- PASG
- Stock Information
- Founded
- LSB 2002
- PASG 2017
- Country
- LSB China
- PASG United States
- Employees
- LSB N/A
- PASG N/A
- Industry
- LSB
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- LSB
- PASG Health Care
- Exchange
- LSB NYSE
- PASG Nasdaq
- Market Cap
- LSB 20.4M
- PASG 20.3M
- IPO Year
- LSB N/A
- PASG 2020
- Fundamental
- Price
- LSB $0.87
- PASG $6.47
- Analyst Decision
- LSB
- PASG Strong Buy
- Analyst Count
- LSB 0
- PASG 3
- Target Price
- LSB N/A
- PASG $153.33
- AVG Volume (30 Days)
- LSB 872.0K
- PASG 104.2K
- Earning Date
- LSB 08-05-2025
- PASG 08-07-2025
- Dividend Yield
- LSB N/A
- PASG N/A
- EPS Growth
- LSB N/A
- PASG N/A
- EPS
- LSB N/A
- PASG N/A
- Revenue
- LSB $79,415,311.00
- PASG N/A
- Revenue This Year
- LSB $39.33
- PASG N/A
- Revenue Next Year
- LSB $75.61
- PASG N/A
- P/E Ratio
- LSB N/A
- PASG N/A
- Revenue Growth
- LSB N/A
- PASG N/A
- 52 Week Low
- LSB $0.36
- PASG $5.12
- 52 Week High
- LSB $6.82
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- LSB 40.85
- PASG 46.17
- Support Level
- LSB $1.02
- PASG $5.12
- Resistance Level
- LSB $1.35
- PASG $7.70
- Average True Range (ATR)
- LSB 0.14
- PASG 0.87
- MACD
- LSB -0.02
- PASG 0.04
- Stochastic Oscillator
- LSB 0.00
- PASG 33.08
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.